CTX-4430: Phase I started

Celtaxsys began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate 4 dose levels of oral CTX-4430 once daily for 15 days in about 36 patients. Celtaxsys acquired the compound from Est...